RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity
Liu, P., Williams, L. D., Shen, X., Bonsignori, M., Vandergrift, N. A., Overman, R. G., Moody, M. A., Liao, H.-X., Stieh, D. J., McCotter, K. L., French, A. L., Hope, T. J., Shattock, R., Haynes, B. F., & Tomaras, G. D. (2014). Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. Journal of Virology, 88(9), 5165-5170. https://doi.org/10.1128/JVI.03765-13
Antibody capacity to recognize infectious virus is a prerequisite of many antiviral functions. We determined the infectious virion capture index (IVCI) of different antibody specificities. Whereas broadly neutralizing antibodies (bNAbs), except for an MPER bNAb, selectively captured infectious virions, non-bNAbs and mucosal human immunodeficiency virus type 1 (HIV-1)-positive IgG captured subsets of both infectious and noninfectious virions. Infectious virion capture was additive with a mixture of antibodies, providing proof of concept for vaccine-induced antibodies that together have improved capacity to recognize infectious virions.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.
